midazolam has been researched along with Chronic Kidney Diseases in 3 studies
Midazolam: A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH.
midazolam : An imidazobenzodiazepine that is 4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted by a methyl, 2-fluorophenyl and chloro groups at positions 1, 6 and 8, respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Midazolam AUC was significantly higher in the HD group (382." | 1.42 | Effect of CKD and dialysis modality on exposure to drugs cleared by nonrenal mechanisms. ( Asher, LJ; Feere, DA; House, AA; Knauer, MJ; Nolin, TD; Thomson, BK; Urquhart, BL; Velenosi, TJ, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Tokunaga, A | 1 |
| Miyamoto, H | 1 |
| Fumoto, S | 1 |
| Nishida, K | 2 |
| Watanabe, H | 1 |
| Sugimoto, R | 1 |
| Ikegami, K | 1 |
| Enoki, Y | 1 |
| Imafuku, T | 1 |
| Fujimura, R | 1 |
| Bi, J | 1 |
| Sakaguchi, Y | 1 |
| Murata, M | 1 |
| Maeda, H | 1 |
| Hirata, K | 1 |
| Jingami, S | 1 |
| Ishima, Y | 1 |
| Tanaka, M | 1 |
| Matsushita, K | 1 |
| Komaba, H | 1 |
| Fukagawa, M | 1 |
| Otagiri, M | 1 |
| Maruyama, T | 1 |
| Thomson, BK | 1 |
| Nolin, TD | 1 |
| Velenosi, TJ | 1 |
| Feere, DA | 1 |
| Knauer, MJ | 1 |
| Asher, LJ | 1 |
| House, AA | 1 |
| Urquhart, BL | 1 |
3 other studies available for midazolam and Chronic Kidney Diseases
| Article | Year |
|---|---|
Effect of Chronic Kidney Disease on Hepatic Clearance of Drugs in Rats.
Topics: Acetaminophen; Adenine; Administration, Intravenous; Animals; Cytochrome P-450 CYP3A; Disease Models | 2020 |
Parathyroid hormone contributes to the down-regulation of cytochrome P450 3A through the cAMP/PI3K/PKC/PKA/NF-κB signaling pathway in secondary hyperparathyroidism.
Topics: Animals; Caco-2 Cells; Cinacalcet; Cyclic AMP; Cytochrome P-450 CYP3A; Down-Regulation; GABA Modulat | 2017 |
Effect of CKD and dialysis modality on exposure to drugs cleared by nonrenal mechanisms.
Topics: Adult; Aged; Aged, 80 and over; Anti-Allergic Agents; Anti-Anxiety Agents; Cytochrome P-450 CYP3A; F | 2015 |